Table 1.

MYC-stabilizing compounds in clinical development

Inhibitor	Mechanism of action	Indication	Stage of development	References
CHIR99021	GSK-3 inhibitor	various xenograft models	Preclinical	Harrington et al., 2019; O’Flaherty et al., 2019
tideglusib	GSK-3 inhibitor	Alzheimer’s disease, myotonic dystrophy	Phase II completed	Lovestone et al., 2015
LY2090314	GSK-3 inhibitor	acute leukemia, metastatic solid cancers	Phase II trials	Rizzieri et al., 2016; Gray et al., 2015
9-ING-41	GSK3-inhibitor	pediatric and adult cancers	Ongoing Phase I/II	Ugolkov et al., 2018
LiCl	GSK-3 inhibitor	bipolar disorders	FDA approved	O’Brien and Klein, 2009
Compound A	Skp2 inhibitor	hematologic malignancies	Preclinical	Chen et al., 2008
C1/C2	Skp2 inhibitor	soft tissue sarcoma	Preclinical	Wu et al., 2012; Li et al., 2020
C25	Skp2 inhibitor	T-ALL, other cancers	Preclinical	Chan et al., 2013; Rodriguez et al., 2020
Dioscin	Degradation of SKP2	colorectal carcinoma	Preclinical	Zhou et al., 2020